Medicare's $50 GLP-1 Bridge Program Explained

Starting July 1, 2026, millions of Medicare beneficiaries will gain access to GLP-1 weight loss medications at a flat $50 monthly copay through a new federal program called the Medicare GLP-1 Bridge. The program represents the first time Medicare has covered any medication specifically for the treatment of obesity, a historic shift in a program that has been legally prohibited from covering weight loss drugs since its inception. For beneficiaries who have been paying hundreds or even thousands of dollars out of pocket for medications like Wegovy and Zepbound, the Bridge program could be transformative.

The program was announced by the Centers for Medicare & Medicaid Services (CMS) as a short-term demonstration that will run through December 31, 2027. It operates entirely outside of the Part D prescription drug benefit, meaning your Part D plan does not need to opt in, and your plan sponsor bears no financial risk. If you are enrolled in a Part D plan and meet the clinical eligibility criteria, you can participate regardless of which plan you are in.

Here is everything you need to know about how the program works, who qualifies, which medications are covered, and what to watch out for.

How the Medicare GLP-1 Bridge Program Works

The Medicare GLP-1 Bridge is a nationwide payment demonstration established by CMS under Section 402 demonstration authority. Unlike a typical Part D benefit change, this program runs through a single central processor that handles prior authorization, claims adjudication, and pharmacy reimbursement. Your Part D plan is not involved in the process.

When you fill a prescription for a covered GLP-1 medication under the Bridge program, you pay a flat $50 copay at the pharmacy. The pharmacy then submits the claim to the CMS central processor for reimbursement. Behind the scenes, CMS reimburses the pharmacy at no lower than the wholesale acquisition cost (WAC) of the drug, minus your $50 copay, plus a dispensing fee and applicable sales tax. The drug manufacturers, Novo Nordisk and Eli Lilly, have agreed to a net price of $245 per monthly supply, and they owe CMS the difference between the WAC and that $245 figure.

For beneficiaries, the mechanics are straightforward: your doctor submits a prior authorization, and once approved, you pick up your medication at the pharmacy for $50 a month. The complexity of the pricing arrangement between CMS, pharmacies, and manufacturers happens entirely behind the counter.

Which Medications Are Covered

Three GLP-1 medications are included in the Bridge program, all approved by the FDA for weight reduction:

It is important to note that the Bridge program covers these drugs only when prescribed for weight management. If you are already receiving a GLP-1 through your Part D plan for a covered indication, such as type 2 diabetes, cardiovascular disease risk reduction, or obstructive sleep apnea, you will continue to get your medication through Part D, not through the Bridge.

Who Qualifies: The Three BMI Tiers

Eligibility for the Medicare GLP-1 Bridge is based on clinical criteria that your healthcare provider must attest to when submitting a prior authorization request. You must be at least 18 years old, enrolled in a Medicare Part D plan, and prescribed the medication specifically to reduce excess body weight in combination with ongoing lifestyle modifications, including structured nutrition and physical activity consistent with the FDA-approved label.

Beyond those baseline requirements, you must fall into one of three BMI-based categories:

Tier 1: BMI of 35 or Higher

If your Body Mass Index is 35 or above at the time you begin GLP-1 therapy, you qualify with no additional diagnostic requirements. This is the most straightforward path into the program.

Tier 2: BMI of 30 or Higher with a Qualifying Condition

If your BMI is at least 30 but below 35, you can still qualify if you have been diagnosed with one or more of the following conditions: heart failure with preserved ejection fraction, uncontrolled hypertension (defined as systolic blood pressure above 140 mm Hg or diastolic above 90 mm Hg despite concurrent treatment with two antihypertensive medications), or chronic kidney disease at stage 3a or above.

Tier 3: BMI of 27 or Higher with a Qualifying Condition

The lowest BMI threshold is 27, but it requires a diagnosis of at least one of these conditions: pre-diabetes as defined by American Diabetes Association guidelines, a previous myocardial infarction (heart attack), a previous stroke, or symptomatic peripheral artery disease.

Your provider handles the prior authorization process, so the most important step on your end is having an honest conversation with your doctor about your weight, your health history, and whether this program is appropriate for you.

What the $50 Copay Does and Does Not Include

The flat $50 monthly copay is one of the most appealing features of the Bridge program, but there are several important nuances to understand.

Because the Bridge operates outside of your Part D benefit, the $50 you pay each month does not count toward your Part D deductible. It also does not count toward the $2,100 annual out-of-pocket maximum in 2026 (rising to $2,400 in 2027). In other words, the money you spend on GLP-1s through the Bridge is completely separate from your Part D spending. Your $50 copay remains the same every month regardless of which Part D benefit phase you are in, whether you are in the deductible phase, the initial coverage phase, or have already hit your out-of-pocket cap.

This distinction matters most for beneficiaries who are also taking expensive Part D medications. The Bridge copay will not help you reach your Part D out-of-pocket maximum any faster.

Who Cannot Use the Bridge Program

The Bridge program was designed specifically for beneficiaries who need GLP-1 medications for weight management. If you have a diagnosis that already qualifies you for GLP-1 coverage under Part D, you are not eligible for the Bridge, even if you also meet the BMI criteria.

The key exclusions are beneficiaries who have been diagnosed with type 2 diabetes, obstructive sleep apnea, or noncirrhotic metabolic dysfunction-associated steatohepatitis (MASH, formerly known as NASH). These conditions have FDA-approved GLP-1 indications that are covered under Part D, so CMS directs those beneficiaries to continue accessing their medications through their existing Part D plan.

This means the Bridge is not a way to get a cheaper copay on a GLP-1 you are already receiving through Part D. It is exclusively for beneficiaries whose primary reason for taking the medication is weight reduction, and who do not have a Part D-covered diagnosis that would provide an alternative coverage pathway.

• Type 2 diabetes (covered under Part D via Ozempic/Mounjaro)

• Obstructive sleep apnea (covered under Part D)

• Noncirrhotic metabolic dysfunction-associated steatohepatitis (MASH/NASH)

• Cardiovascular disease risk reduction (if already receiving GLP-1 through Part D for this indication)

How to Get Started

Enrolling in the Medicare GLP-1 Bridge is not something you do yourself. It begins with your healthcare provider. Here is the general process:

1. Schedule an appointment with your doctor to discuss whether GLP-1 therapy is appropriate for your situation. Your provider will evaluate your BMI, review your medical history for qualifying conditions, and determine which of the three eligibility tiers applies to you.

2. If your doctor determines you are a good candidate, they will submit a prior authorization request to the CMS central processor. This request includes an attestation that you meet the clinical criteria and that the medication is being prescribed for weight management in combination with lifestyle modifications.

3. Once the prior authorization is approved, you can fill your prescription at a participating pharmacy. You will pay the $50 copay at the counter, and the pharmacy handles the rest of the claims process with CMS.

Why the Bridge Exists: The BALANCE Model Delay

To understand why the Bridge program was created, and why it was extended, it helps to know about the BALANCE Model. BALANCE stands for Better Approaches to Lifestyle and Nutrition for Comprehensive hEalth, and it was CMS's original plan for a longer-term expansion of GLP-1 coverage in both Medicare and Medicaid.

The BALANCE Model was designed as a voluntary program where Part D plan sponsors would opt in to cover GLP-1s for obesity at negotiated prices, with manufacturers also providing free lifestyle support programs to participants. CMS set an 80 percent participation threshold, meaning that plans covering at least 80 percent of Part D enrollment needed to sign up for the model to move forward.

That threshold was not met. On April 21, 2026, one day after the application deadline, CMS announced that major Part D plan sponsors were reluctant or unwilling to participate in the BALANCE Model as originally designed. The estimated cost of covering obesity drugs under Part D has been projected at $25 billion to $35 billion over 10 years, and plan sponsors apparently lacked sufficient data to estimate their added costs.

Rather than leave Medicare beneficiaries without any coverage pathway, CMS extended the Bridge program from its original December 2026 end date through December 31, 2027. The BALANCE Model is still moving forward for Medicaid (where it began in May 2026), but its implementation in Medicare Part D has been delayed indefinitely.

What Happens After December 2027

This is the question that does not yet have a clear answer. When the Medicare GLP-1 Bridge expires at the end of 2027, there is currently no guaranteed coverage pathway for Medicare beneficiaries who are taking GLP-1s for obesity.

CMS has indicated that the Bridge extension will allow for collection of additional utilization data that could be shared with Part D plan sponsors to encourage future participation in the BALANCE Model. But no specific timeline has been announced for restarting or restructuring that model for Medicare.

There are a few possible scenarios. CMS could extend the Bridge program again. The BALANCE Model could be redesigned with terms more attractive to Part D sponsors and relaunched in 2028 or later. Congress could act to lift the statutory prohibition on Medicare covering weight loss drugs, which would make the issue moot. Or none of these things could happen, and beneficiaries could lose access.

The Bigger Picture: GLP-1 Affordability in Medicare

The creation of the Bridge program reflects just how dramatically the landscape around GLP-1 medications has shifted. According to KFF polling, about 56 percent of GLP-1 users say these drugs are difficult to afford, with one in four describing them as "very difficult" to afford. The retail prices for medications like Wegovy and Zepbound can exceed $1,000 per month without insurance coverage, putting them out of reach for most Medicare beneficiaries paying out of pocket.

The Trump administration has pursued multiple approaches to bring down GLP-1 costs, including "most-favored nation" pricing deals with Novo Nordisk and Eli Lilly, the TrumpRx discount program, and the BALANCE Model demonstration. Separately, semaglutide (the active ingredient in Wegovy and Ozempic) was selected for Medicare drug price negotiation in 2025, with a negotiated price set to take effect in 2027.

The Bridge program is a temporary but meaningful step that demonstrates Medicare can provide access to weight loss medications at an affordable price point. Whether that access becomes permanent will depend on the political, regulatory, and financial dynamics that play out over the next 18 months.

Frequently Asked Questions